Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 60.8%

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 22,600 shares, a drop of 60.8% from the December 15th total of 57,600 shares. Based on an average daily volume of 175,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the shares of the company are short sold.

Adial Pharmaceuticals Price Performance

Shares of ADIL stock opened at $1.02 on Thursday. Adial Pharmaceuticals has a one year low of $0.77 and a one year high of $4.17. The stock has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.04.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. RODMAN&RENSHAW raised shares of Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw initiated coverage on Adial Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $8.00 price target for the company.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.